Anemia due to chronic kidney disease (CKD)¹

PROCRIT^® is indicated for the treatment of anemia due to CKD, including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.

PROCRIT^® has not been shown to improve quality of life, fatigue, or patient well-being.

PROCRIT^® is not indicated for use:

• In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy
• In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure
• In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion
• In patients scheduled for surgery who are willing to donate autologous blood
• In patients undergoing cardiac or vascular surgery
• As a substitute for RBC transfusions in patients who require immediate correction of anemia

When treating anemia in CKD patients not on dialysis

• In 4 studies of adult CKD patients not on dialysis, those on PROCRIT^® (n=181) demonstrated a dose-dependent and sustained increase in hemoglobin when PROCRIT^® was administered by either an intravenous or subcutaneous route¹

Selected safety profile¹

WARNINGS: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE

Chronic Kidney Disease:

• In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis‍-‍stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL
• No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks
• Use the lowest PROCRIT^® dose sufficient to reduce the need for red blood cell (RBC) transfusions

Expand the Important Safety Information at the bottom of the page to see the complete Boxed Warnings.

The adverse reactions with a reported incidence of ≥5% in PROCRIT^®-treated patients and that occurred at a ≥1% higher frequency than in placebo-treated patients are shown in the table below:

Adverse reactions in patients with CKD not on dialysis¹

• From 2 double-blind, placebo-controlled studies in 210 patients with CKD not on dialysis¹